Executive summary

The International AIDS Conference (IAS) is one of the world’s most influential global health and HIV-focused meetings, convening scientists, clinicians, public health leaders, policymakers, advocates, funders, program implementers, and industry stakeholders. Compared to general medical conferences, IAS tends to attract a higher density of cross-functional decision-makers—people who bridge evidence generation (research), clinical translation (treatment guidelines), and implementation (public health programs), plus organizations supporting supply chains, diagnostics, digital health, data, and community-led outcomes.

For buyer-focused research, IAS is strongest when we target companies and institutions that either (1) develop and commercialize HIV-related therapies and prevention tools, (2) provide diagnostics and lab/clinical workflow technologies, (3) run large public health programs or procurement frameworks, or (4) influence funding, policy, and implementation strategy across regions.

Event basics (where/when)

Event title: International AIDS Conference (IAS)
Frequency: Biennial (commonly held every two years; verify the specific edition for exact dates/venue)
Venue: Varies by edition (verify for the exact city/country of the next IAS conference)
Event type: Global Health / HIV Science & Policy / Clinical Research & Implementation / Industry & Partner Forum

If the specific edition’s city and dates are available from the client brief, we can tailor the “Where + origin” and “estimated attendance” sections more precisely (and refine buyer prioritization by local/regional procurement influence).

1) Who attends (BUYERS / ATTENDEES)

IAS attendance is typically multi-stakeholder and includes both knowledge buyers (who influence decisions) and commercial buyers (who purchase or authorize solutions). While attendee composition varies by edition, the best “buyer” segments generally include:

A. Clinical and scientific decision-makers (high influence)

• Infectious disease physicians and HIV specialists (including guideline-influencing clinicians)
• Clinical research leaders, principal investigators, translational scientists
• Medical affairs leaders (therapy positioning, evidence synthesis, guideline support)
• Pharmacovigilance / outcomes researchers who shape adoption of interventions

B. Public health & implementation leaders (implementation buyers)

• National AIDS program (NAP) managers and program directors
• Public health department leaders and prevention strategy teams
• Program implementers from NGOs and international development organizations
• Procurement and supply program managers (antiretrovirals, prevention commodities, diagnostics)

C. Diagnostics, lab, and clinical workflow leaders (solution buyers)

• Head(s) of laboratory services, clinical testing directors
• Diagnostics procurement and regulatory-affairs teams
• Quality systems leaders for lab operations and point-of-care implementation

D. Industry partners (commercial buyers and strategic partners)

• Business development and partnerships executives
• Market access leaders (pricing, reimbursement pathways, adoption evidence)
• Government affairs / public policy stakeholders
• Field medical affairs and global portfolio teams

Best buyer framing for IAS: “Evidence-to-implementation” buyers—people who connect research outcomes to real-world uptake (treatment, prevention, diagnostics, and program scale-up).

2) Where the show is happening + attendee geographic origin

Show location: Depends on the specific IAS edition (city/country varies).
Attendee geographic origin (typical IAS pattern): Strong global mix with a major emphasis on:

• Global North: United States, Canada, Western Europe, Australia/NZ (industry, research institutions, major clinical networks)
• Global South: Sub-Saharan Africa, Latin America, Eastern Europe, Middle East & North Africa (program implementation, national strategies, field research communities)
• International organizations: Often represented across regions through collaborations, funding, and technical assistance programs

In practical targeting, the “geographic origin” matters because buyers often map to local adoption pathways:

• Procurement and program leaders may favor routes aligned with their national or regional priorities.
• Diagnostics and pharmaceutical market access teams focus on evidence that supports adoption in multiple regulatory environments.
• Industry partnerships often target regions where trial sites, implementation programs, and scale-up momentum are strongest.

3) Audience reach (Local / National / Global)

IAS is a global event by design. Even when the host city is in a specific country, the attendee base typically spans:

• Global participation: Researchers, clinicians, and program implementers from many countries and regions
• International policy and funding presence: Stakeholders who influence cross-border collaboration and priority setting
• Cross-sector reach: Health systems, NGOs, diagnostics, pharma, digital health, and implementation partners

Audience reach classification: Global (with meaningful hubs across North America, Europe, and high-burden regions)

4) Sample buyer company names (BUYERS ONLY) + Websites

Below is a buyer-oriented sample list of organizations that are highly likely to have strategic or procurement/implementation interest at an HIV-focused global conference like IAS. These are intended for targeting research and outreach prioritization.

Note: We can refine this sample list to only include 100% relevant buyer types based on the client product category (e.g., therapeutics, diagnostics, clinical trial services, lab instruments, digital health, or program implementation support). We can also ensure the table contains only real, directly relevant buyer accounts once the client product is confirmed.

5) Job profiles, industries & event type

A. Best job profiles to target (IAS-specific buyer roles)

• Medical Affairs & Clinical Translation: Head of Medical Affairs, Director Medical Affairs, Medical Strategy Lead
• Clinical Development & Trials: Director Clinical Trials, VP Clinical Development, Trial Operations Lead
• Market Access & Evidence: Head of Market Access, Reimbursement Strategy Lead, Health Economics & Outcomes Lead
• Diagnostics & Lab Procurement: Director Diagnostics Strategy, Lab Operations Director, Head of Clinical Testing Procurement
• Public Health & Program Partnerships: Partnerships Director, Program Implementation Lead, Public Health Strategy Director
• Supply Chain & Implementation Ops: Procurement Manager (Healthcare), Program Supply Lead, Logistics & Distribution Manager
• Regulatory & Quality: Regulatory Affairs Director, Quality Systems Lead, Clinical Quality Manager
• Data & Digital Health: Healthcare Data Partnerships Lead, Clinical Data Strategy Manager, Digital Health Product Lead

B. Event type (how IAS typically “sells” internally)

• Research + clinical translation: presentations, late-breaking studies, translational science sessions
• Policy + implementation: guideline impacts, program scale-up frameworks, health systems topics
• Industry innovation: diagnostics, treatment monitoring tools, digital health enablement, partnerships
• Global stakeholder networking: convenes institutional and cross-border collaboration

6) Estimated attendance (expected total footfall)

Estimated attendance can vary significantly by the specific edition and venue scale. For a realistic planning range:

• Expected total attendance: approximately 10,000–20,000 (including delegates, scientific attendees, exhibitors, media/NGO representatives, and partners)
• Buyer density: Typically lower than purely commercial trade shows, but strong in “strategic decision-maker presence” across pharma, diagnostics, digital health, and public health leadership
• Where buyer density concentrates: plenaries, late-breaking science events, exhibit partner halls, satellite sessions, and industry roundtables

For more accurate footfall estimates, we should confirm the specific IAS edition (year + city) and whether the conference includes expanded co-located meetings and how exhibitor hall footprint is configured.

7) Key focus areas & buyer engagement

A. Key focus areas that attract buyers

• HIV prevention and risk reduction: prevention strategies, adherence, and novel approaches
• Antiretroviral therapy outcomes: real-world effectiveness, long-term monitoring, resistance patterns
• Testing and diagnosis pathways: scale-up of testing, linkage to care, diagnostic innovation
• Cure research and advanced therapies: translational and investigative science
• Health equity and access: adoption barriers, supply continuity, affordability, and community impact
• Implementation science: scaling models, service delivery optimization, and workforce/system readiness
• Digital health and data interoperability: care coordination, reporting, and outcomes measurement
• Clinical trial operations: partnerships, sites, protocols, governance, and data management

B. How buyers engage at IAS (practical outreach angle)

• Evidence and implementation alignment: Buyers often look for solutions that can be validated with clinical/public health evidence.
• Partnership-led conversations: Many buyers engage through collaborations, pilots, and multi-stakeholder initiatives.
• Regional adoption needs: Buyers care about country-level constraints and implementation readiness.
• Supply and reliability: Especially relevant for diagnostics and healthcare commodities, including continuity planning.

Best buyer engagement positioning: “We help improve outcomes through evidence-backed adoption—faster testing, better linkage to care, and measurable implementation impact.”

8) Client-product fit check (required input) + buyer recommendation logic

We can shortlist the best buyer types (and the corresponding company list) based on what our client product actually does. Please share:

• Your client website URL
• 1–2 sentence product summary (what it does, who it serves)
• Geographies targeted (if any) and buyer type preference (pharma/diagnostics/digital health/public sector/NGO)

Once we review the client website, we will map the product category to the most likely IAS buyer segments and provide: (1) the highest-priority buyer titles, (2) the best-matching company accounts, (3) a refined buyer spreadsheet-ready table (with priority scoring).

How we will recommend buyers based on product categories (preliminary)

• If the product is HIV therapeutics / prevention medicines: prioritize clinical development, medical affairs, and market access decision-makers in large pharma and specialty HIV-focused companies.
• If the product is diagnostics / lab instruments / point-of-care testing: prioritize diagnostics strategy, lab operations, and procurement roles at diagnostics and healthcare technology companies.
• If the product is digital health / data / care coordination: prioritize digital health product leads, healthcare data partnership leads, and implementation partners focused on outcomes measurement.
• If the product is clinical trial services / CRO / lab services: prioritize trial operations, clinical operations, and data governance leaders.
• If the product is program implementation support / training / supply chain enablement: prioritize public health program leadership, partnerships, and procurement/supply managers in international health organizations and NGOs.

Until we receive the client website, the list in Section 4 should be treated as a starter buyer map rather than the final “best buyers” set.

9) Industry suggestions (aligned to the available industry list)

Based on IAS’s typical ecosystem, we recommend the following industry filters when building target accounts:

• Pharmaceuticals
• Biotechnology
• Medical Devices
• Hospital & Health Care
• Medical Practice
• Research
• Public Policy
• Nonprofit Organization Management
• Internet and/or Information Technology & Services (if digital health/data are involved)
• Information Services (if analytics/reporting data solutions are involved)

If the client product is in logistics for healthcare commodities, we can also add: Logistics & Supply Chain and Warehousing. If it’s education/training for healthcare workers, we can add: Professional Training & Coaching.

Final buyer-fit rating (for IAS attendee ecosystem)

• Strategic relevance: High (IAS is central to HIV clinical and public health ecosystems)
• Buyer decision-maker concentration: Medium to High (strong for pharma, diagnostics, clinical ops, and health program leadership)
• Best use case for our research: Buyer-focused targeting for evidence-driven adoption, implementation, diagnostics, and partnerships

Once the client website is shared, we will convert the general buyer map into a prioritized “best buyer” shortlist aligned to the exact solution category and buyer roles.

Next step (client input needed)

Please share the client website URL so we can review it and return the best buyers for IAS that match our client’s requirements. We will then finalize:

• Best buyer titles to target
• Top company shortlist
• Industry filter set
• Priority scoring for outreach